Nano-particle pills could one day replace a host of medications for diseases such as diabetes and cancer that now have to be injected, research suggests.
Scientists are working on a new kind of pill loaded with microscopic drug capsules that can safely pass through the intestinal wall.
Early tests have already shown how one oral nano-particle containing insulin can reduce blood sugar levels in mice.
Currently, diabetics lacking the hormone have to self-inject it, sometimes several times a day.
The development of an insulin pill would transform the management of type-1 diabetes.
Future nano-particle pills may also be used to deliver drugs across other natural barriers surrounding the brain, lungs and placenta.
“Being able to deliver nano-medicine orally would offer clinicians broad and novel ways to treat today’s many chronic diseases that require daily therapy, such as diabetes and cancer,” said Professor Robert Langer, a member of the research team from the Massachusetts Institute of Technology in Boston, US.
Nano-particles are being actively explored by numerous research groups as “smart” drug delivery systems that could be designed to target specific cells, or time the release of medicines.
Typically they consist of tiny spheres of synthetic material holding the desired medication within a hollow core, or dispersed throughout the particle body, or attached to its surface. By definition, a nano-particle is an object up to a millionth of a millimetre across.
Until now, nano-particles have only been considered as injectible treatments because of their inability to penetrate the cellular barrier lining the gut.
Scientists solved the problem by mimicking the way babies absorb antibodies from their mothers’ milk to boost their immune systems.
The antibodies attach onto “receptor” molecules on the intestinal wall cell surface that act like gates, allowing access to adjacent blood vessels.
“The novelty of actively being able to transport targeted nano-particles across cell barriers can potentially open up a whole new set of opportunities in nano- medicine,” said study leader Dr Omid Farokhzad, director of the Brigham and Women’s Hospital Laboratory of Nanomedicine and Biomaterials in Boston.
© Irish Examiner Ltd. All rights reserved